Goldman Sachs Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (Iovance or the Company) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address,... More

Scott+Scott Attorneys at Law LLP Continues to Remind Investors There is a Securities Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA)

New York, New York--(Newsfile Corp. - June 2, 2025) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, "Defendants"). The Class Action asserts claims under 10(b)... More

The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

One-time Amtagvi Treatment Continues to Show 
Deep, Durable Responses and Meaningful Survival

One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years

Simultaneous Presentation at ASCO 2025

SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has... More

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may... More

IOVA CLASS ALERT: Iovance Biotherapeutics, Inc. Investors with Losses are Notified to Contact BFA Law about the Securities Fraud Class Action

New York, New York--(Newsfile Corp. - June 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws.

If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.

Investors... More

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA

New York, New York--(Newsfile Corp. - May 30, 2025) - WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Iovance class... More

Scott+Scott Attorneys at Law LLP Reminds Investors of The Securities Class Action That Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)

New York, New York--(Newsfile Corp. - May 30, 2025) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, "Defendants"). The Class Action asserts claims under 10(b)... More

IOVA DEADLINE: BFA Law Alerts Iovance Biotherapeutics, Inc. Investors of the Pending July 14 Class Action Deadline

New York, New York--(Newsfile Corp. - May 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws.

If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.

Investors... More